NEOHealthcare · Diagnostics & ResearchThe 12 Wall Street analysts covering NeoGenomics, Inc. hold a median 12-month price target of $19 — +8.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 31 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores NeoGenomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Volatility (28): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +8.9% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | Needham | Maintains | Buy | $15 → $19 |
| 24 July 2026 | Benchmark | Maintains | Buy | $11 → $16 |
| 29 Apr 2026 | Benchmark | Upgrade | Buy | — |
| 29 Apr 2026 | Benchmark | Upgrade | Buy | $11 |
| 29 Apr 2026 | Leerink Partners | Upgrade | Outperform | $12 → $25 |
| 29 Apr 2026 | Leerink Partners | Upgrade | Outperform | — |
| 29 Apr 2026 | TD Cowen | Maintains | Buy | $13 → $14 |
| 29 Apr 2026 | TD Cowen | Maintains | Buy | — |
| 24 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Feb 2026 | Needham | Maintains | Buy | — |
| 12 Jan 2026 | Needham | Reiterates | Buy | — |
| 12 Sept 2025 | TD Cowen | Maintains | Buy | — |
| 2 Sept 2025 | Stephens & Co. | Maintains | Overweight | — |
| 29 Aug 2025 | Needham | Maintains | Buy | — |
| 4 Aug 2025 | Piper Sandler | Maintains | Overweight | — |
| 30 July 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 29 July 2025 | Needham | Maintains | Buy | — |
| 29 July 2025 | William Blair | Downgrade | Market Perform | — |
| 6 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 1 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEO appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 1 Sept 2026, NeoGenomics, Inc. returned +98.7% against +19.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 41% of US stocks
Cheaper than 35% of US stocks
Cheaper than 2% of US stocks
Higher than 55% of US stocks
Higher than 49% of US stocks
Higher than 57% of US stocks
Higher than 28% of US stocks
Higher than 22% of US stocks
Higher than 38% of US stocks
Higher than 37% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeoGenomics, Inc. has a market value of $2.3B and an enterprise value of $2.6B.
Revenue in the twelve months to 30 June 2026: $766.3M. The latest quarter grew 11.2% year on year.
Net income over the same four quarters: −$51.9M, a −6.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.40.
Free cash flow in the twelve months to 30 June 2026: −$7.4M.
Trailing P/E: −20.8×; forward P/E: 50.8× — the forward figure prices analyst consensus estimates, not reported earnings.
NeoGenomics, Inc. employs 2,500 people — $307K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeoGenomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeoGenomics announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14–16, 2026, in New York.
Why it matters — Participation in a major healthcare conference gives NeoGenomics a platform to present to investors and industry peers, which NEO watchers may see as a routine opportunity for visibility.
NeoGenomics announced expanded Medicare MolDX coverage for its RaDaR ST minimal residual disease (MRD) assay, which is used for immunotherapy treatment response monitoring in late-stage solid tumors. The announcement was made via Business Wire from Fort Myers, Florida.
Why it matters — Expanded Medicare coverage for RaDaR ST could broaden access and adoption of NeoGenomics' MRD testing in immunotherapy monitoring for late-stage solid tumor patients.
Neo Performance Materials (TSE: NEO) reported record second-quarter results, driven by higher volumes, favorable pricing and lower conversion costs across its business segments. The company reaffirmed its expectation to reach the high end of its increased 2026 adjusted EBITDA guidance.
Why it matters — The record quarterly results and reaffirmed upwardly revised 2026 adjusted EBITDA guidance signal sustained operational momentum across Neo Performance Materials' business segments.
NeoGenomics, Inc. (NEO) has reached a 52-week high, and the article considers whether investors can expect further gains by looking at the company's fundamentals for clues.
Why it matters — A NEO watcher would care because the article assesses whether the company's fundamentals support continued gains after hitting a 52-week high.
NeoGenomics held its Q2 2026 earnings call, and the transcript of that call was published by Seeking Alpha.
Why it matters — Earnings-call transcripts provide investors and analysts with a full, unedited account of management's commentary on the quarter's results and outlook.
The 12 Wall Street analysts covering NeoGenomics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering NeoGenomics, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeoGenomics, Inc. 75 out of 100 across roughly 4,600 US stocks as at 31 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Aug 2026, NeoGenomics, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +8.9% from the last close, and Ticker Nerd's factor model ranks NeoGenomics, Inc. 75 out of 100 as at 31 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeoGenomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $35 over the next 12 months.
NeoGenomics, Inc. returned +98.7% over the 12 months to 1 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services.
The most recent item we track (Business Wire, 1 Sept 2026): "NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference". NeoGenomics announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14–16, 2026, in New York.
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, and pathology support. Its services are used by oncologists, pathologists, hospitals, academic medical centers, and pharmaceutical companies to help characterize disease, guide treatment decisions, and support clinical research and drug development. NeoGenomics operates a network of cancer-focused laboratories in the United States and the United Kingdom, with business operations organized around Clinical Services and Advanced Diagnostics. Headquartered in Fort Myers, Florida, NeoGenomics plays a specialized role in precision medicine by delivering laboratory data and expert interpretation for cancer diagnosis and care.
CEO Mr. Anthony P. Zook · 2,500 employees · United States · https://www.neogenomics.com
